Press Release: Kernel : Kernel's Revolutionary Neuroimaging Technology, Flow1, Validated in Published Feasibility Study on Measuring Psychedelic Effects

LOS ANGELES--(BUSINESS WIRE)--Kernel, a leader in non-invasive neuroimaging, announces the publication of their study "Measuring acute effects of subanesthetic ketamine on cerebrovascular hemodynamics in humans using TD-fNIRS," in the journal Scientific Reports from the Nature Portfolio of Journals. The study, sponsored by Cybin Inc. (NEO:CYBN) (NYSE American:CYBN), underscores the ability of Kernel's Flow1 system to capture and analyze brain changes resulting from the administration of a psych